Skip to main content
Clinical Trials/NCT00829556
NCT00829556
Completed
N/A

Single-Center, Randomized Trial to Study the Efficacy of InteguSeal for Surgical Skin Preparation in Patients Undergoing

Rothman Institute Orthopaedics1 site in 1 country160 target enrollmentApril 2008

Overview

Phase
N/A
Intervention
Not specified
Conditions
Prosthetic Joint Infection
Sponsor
Rothman Institute Orthopaedics
Enrollment
160
Locations
1
Primary Endpoint
The primary endpoint of the study will be to determine the incidence of postoperative wound drainage during hospital stay when adding Integuseal to the normal surgical skin preparation.
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

This study is being conducted to investigate the potential benefits of using a special type of fluid that can be applied to the skin (Integuseal) in addition to standard surgical skin preparation in patients undergoing total hip replacement (THA) or total knee replacement (TKA). Integuseal is supposed to lock down the skin bacteria and reduce skin infection and other problems. This study will investigate whether Integuseal is effective in reducing persistent wound drainage when used in addition to standard surgical skin preparation for total hip arthroplasty (THA) or total knee replacement (TKA).

Registry
clinicaltrials.gov
Start Date
April 2008
End Date
September 2009
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Subjects who are able and willing to provide informed consent;
  • Male and non-pregnant, non-lactating, female subjects who are willing to practice effective means of contraception or postmenopausal/surgically sterilized female subjects, between the ages of 18-80 years old, of any ethnic origin.
  • Subjects deemed able to comply with study schedule visits, procedures and medications as specified by the protocol.
  • Subjects undergoing elective THA or TKA procedures.
  • Subjects in satisfactory health as determined by the investigator on the basis of medical history and physical examination.

Exclusion Criteria

  • Subjects undergoing revision, hemiarthroplasty, or bilateral THA or TKA
  • Subjects undergoing non-elective THA or TKA procedures.
  • Pregnant or lactating females or females of childbearing potential not practicing an effective method of contraception.
  • Subjects with known allergies to iodine and/or chlorhexidine

Outcomes

Primary Outcomes

The primary endpoint of the study will be to determine the incidence of postoperative wound drainage during hospital stay when adding Integuseal to the normal surgical skin preparation.

Time Frame: Total joint replacement to discharge from hospital

Secondary Outcomes

  • To evaluate the effect of using Integuseal on the length of hospital stay after THA or TKA.(Total joint replacement to discharge from hospital)
  • To evaluate the effect of using Integuseal on the incidence of surgical site infection (SSI).(6 weeks)
  • To evaluate the effect of using Integuseal on the incidence of revision or re-admission after undergoing THA or TKA(6 weeks)

Study Sites (1)

Loading locations...

Similar Trials